Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;49(2):1413-1427.
doi: 10.1007/s11033-021-06890-0. Epub 2021 Nov 3.

New insights into the role of fibroblast growth factors in Alzheimer's disease

Ramy Alam #  1 , Yara Mrad #  2 , Hussein Hammoud #  1 , Zahraa Saker #  1 , Youssef Fares  1   3 , Elias Estephan  1 , Hisham F Bahmad  4 , Hayat Harati  5 , Sanaa Nabha  6
Affiliations
Review

New insights into the role of fibroblast growth factors in Alzheimer's disease

Ramy Alam et al. Mol Biol Rep. 2022 Feb.

Abstract

Alzheimer's disease (AD), acknowledged as the most common progressive neurodegenerative disorder, is the leading cause of dementia in the elderly. The characteristic pathologic hallmarks of AD-including the deposition of extracellular senile plaques (SP) formation, intracellular neurofibrillary tangles, and synaptic loss, along with prominent vascular dysfunction and cognitive impairment-have been observed in patients. Fibroblast growth factors (FGFs), originally characterized as angiogenic factors, are a large family of signaling molecules that are implicated in a wide range of biological functions in brain development, maintenance and repair, as well as in the pathogenesis of brain-related disorders including AD. Many studies have focused on the implication of FGFs in AD pathophysiology. In this review, we will provide a summary of recent findings regarding the role of FGFs and their receptors in the pathogenesis of AD, and discuss the possible opportunities for targeting these molecules as novel treatment strategies in AD.

Keywords: Alzheimer’s disease; Fibroblast growth factor; Fibroblast growth factor receptor; Neuroprotection; Therapeutic target.

PubMed Disclaimer

References

    1. Zhang XX et al (2021) The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimers Dis 8(3):313–321 - PubMed
    1. Morris JC (1997) Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9(Suppl 1):173–6 (discussion 177–8)
    1. Lyketsos CG et al (2003) Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 60(7):737–746 - PubMed
    1. Gorevic PD et al (1986) Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer’s disease: immunohistological studies. J Neuropathol Exp Neurol 45(6):647–664 - PubMed
    1. Dorszewska J et al (2016) Molecular basis of familial and sporadic Alzheimer’s disease. Curr Alzheimer Res 13(9):952–963 - PubMed

Substances

LinkOut - more resources